Translation of novel anti-cancer cytotoxicity biomarkers detected with high content analysis from an in vitro predictive model to an in vivo cell model

Toxicology in Vitro

Volumn 24, Issue 8, 2010, Pages 2063-2071

  Lieggi, N T ^a   Edvardsson, A ^a   O'Brien, P J ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Cancer; Cytotoxicity; HCA; Human; Multi parameter; Sub lethal

Indexed keywords

ARSENIC TRIOXIDE; BIOLOGICAL MARKER; CALCIUM; CELL DNA; CYTARABINE; DOXORUBICIN; DYE; HOE 33342; MITOXANTRONE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL ASSAY; CELL COUNT; CELL MEMBRANE PERMEABILITY; CELL NUCLEUS; CELL STRAIN HEPG2; CELL SUSPENSION; CONTENT ANALYSIS; CONTROLLED STUDY; DNA DETERMINATION; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTERCALATION COMPLEX; LEUKEMIA CELL LINE; LIVER CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; PREDICTION; T LYMPHOCYTE;

ANTINEOPLASTIC AGENTS; BIOLOGICAL ASSAY; BIOLOGICAL MARKERS; CYTOTOXINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; HEP G2 CELLS; HUMANS; JURKAT CELLS; MODELS, BIOLOGICAL; P-GLYCOPROTEIN; TOXICITY TESTS;

EID: 78449306689     PISSN: 08872333     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tiv.2010.07.014     Document Type: Article

References (19)

1. Abraham V.C., Towne D.L., Waring J.F., Warrior U., Burns D.J. Application of a high-content multiparameter cytotoxicity assay to prioritize compounds based on toxicity potential in humans. J. Biomol. Screen. 2008, 13:527-537.
2. Anderson A.B., Gergen J., Arriaga E.A. Detection of doxorubicin and metabolites in cell extracts and in single cells by capillary electrophoresis with laser-induced fluorescence detection. J. Chromatogr. B 2002, 769:97-106.
3. Calabrese E.J., Baldwin L.A. Applications of hormesis in toxicology, risk assessment and chemotherapeutics. Trends Pharmacol. Sci. 2002, 23:331-337.
4. Domingos, M., Magowitz, J., Sayers, G., Davies, A.M., O'Brien, P.J., 2008. Application of high content analysis in clinical cytology for translational safety biomarkers of drug-induced toxicity for lymphoma chemotherapy. In: Proceedings of Eighth Congress of European Society of Veterinary Clinical Pathology, Barcelona.
5. Hajian R., Shams N., Mohagheghian M. Study on the interaction between doxorubicin and deoxyribonucleic acid with the use of methylene blue as a probe. J. Brazil. Chem. Soc. 2009, 20:1399-1405.
6. Huang R.F., Ho Y.H., Lin H.L., Wei J.S., Liu T.Z. Folate deficiency induces a cell cycle-specific apoptosis in HepG2 cells. J. Nutr. 1999, 129:25-31.
7. Jan E., Byrne S.J., Cuddihy M., Davies A.M., Volkov Y., Gun'ko Y.K., Kotov N.A. High-content screening as a universal tool for fingerprinting of cytotoxicity of nanoparticles. ACS Nano. 2008, 2:928-938.
8. Malatesta V., Andreoni A. Dynamics of anthracyclines/DNA interaction: a laser time-resolved fluorescence study. Photochem. Photobiol. 1988, 48:409-415.
9. O'Brien P.J. Chapter 13: high content analysis of sublethal cytotoxicity in human HepG2 hepatocytes for assessing potential and mechanism for chemical and drug-induced human toxicity. High Content Screening: Science, Techniques and Applications 2008, 293-316. John Wiley and Sons, Hoboken, NJ. S.A. Haney (Ed.).
10. O'Brien P.J. Discovery toxicology screening: predictive, in vitro cytotoxicity. Hit and Lead Profiling 2009, 325-343. Wiley-VCH Verlag GmbH and Co. KGaA, Weinheim. B. Faller, L. Urban (Eds.).
11. O'Brien P.J., Haskins J.R. In vitro cytotoxicity assessment. Methods Mol. Biol. 2007, 356:415-425.
12. O'Brien P.J., Irwin W., Diaz D., Howard-Cofield E., Krejsa C.M., Slaughter M.R., Gao B., Kaludercic N., Angeline A., Bernardi P., Brain P., Hougham C. High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening. Arch. Toxicol. 2006, 80:580-604.
13. Olson H.M., Kadyszewski E., Beierschmitt W. Hormesis - a pharmaceutical industry perspective. Crit. Rev. Toxicol. 2001, 31:659-661.
14. Qu Q., Chu J.W.K., Sharom F.J. Transition state P-glycoprotein binds drugs and modulators with unchanged affinity, suggesting a concerted transport mechanism. Biochemistry 2003, 42:1345-1353.
15. Regev R., Katzir H., Yeheskely-Hayon D., Eytan G.D. Modulation of P-glycoprotein-mediated multidrug resistance by acceleration of passive drug permeation across the plasma membrane. FEBS J 2007, 274:6204-6214.
16. Schoonen W.G.E.J., Westerink W.M.A., de Roos J.A.D.M., Debiton E. Cytotoxic effects of 100 reference compounds on Hep G2 and HeLa cells and of 60 compounds on ECC-1 and CHO cells. I. Mechanistic assays on ROS, glutathione depletion and calcium uptake. Toxicol. in Vitro 2005, 19:505-516.
17. Schoonen W.G.E.J., Westerink W.M.A., de Roos J.A.D.M., Debiton E. Cytotoxic effects of 110 reference compounds on Hep G2 and for 60 compounds on HeLa, ECC-1 and CHO cells. I. Mechanistic assays on NAD(P)H, ATP, and DNA contents. Toxicol. in Vitro 2005, 19:491-503.
18. Xu J.J., Diaz D., O'Brien P.J. Applications of cytotoxicity assays and pre-lethal mechanistic assays for assessment of human hepatotoxicity potential. Chem.-Biol. Interact. 2004, 150:115-128.
19. Xu J.J., Henstock P.V., Dunn M.C., Smith A.R., Chabot J.R., de Graaf D. Cellular imaging predictions of clinical drug-induced liver injury. Toxicol. Sci. 2008, 105:97-105.